(Updates with further details and background)
March 20 (Reuters) - Australian Clinical Labs (ACL) said on Monday it will acquire Healius (HLS) through an all-share takeover, valuing the medical center operator at A$1.52 billion ($1.02 billion).
The pathology firm said it will offer 0.74 share for every Healius share. The offer price represents a discount of about 4.2% to Healius' last close.
If the deal is successful, Healius' shareholder will own 68% of the merged entity, the company said in a statement.
In 2020, Healius rejected a $1.3 billion buyout offer from Partners Group, saying at the time it undervalued the medical center operator.
($1 = 1.4896 Australian dollars)
News: HLS UPDATE 1-Australian Clinical Labs offers to buy Healius for $1 billion
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
79.3¢ |
Change
-0.018(2.16%) |
Mkt cap ! $575.4M | |||
| Open | High | Low | Value | Volume |
| 80.0¢ | 80.8¢ | 79.0¢ | $940.7K | 1.177M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 54 | 214577 | 79.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 79.5¢ | 67501 | 24 |
View Market Depth
| Last trade - 13.39pm 10/09/2025 (20 minute delay) ? |
| HLS (ASX) Chart |